Eventum Orthopaedics develops the QuadSense device to give surgeons real-time data to precisely cut and position the kneecap in total knee replacements. The device has UK and US regulatory approvals and has been used in over 300 procedures. The company says better kneecap positioning can address patient dissatisfaction—around 20% of knee replacement patients are not fully satisfied and one in ten is very dissatisfied. Founded in 2020, Eventum has appointed distributors in the UK, US and other international markets and is rolling the product out internationally. It is developing similar devices for shoulder and hip operations. The company has raised a total of £7 million to date and will use the new funding to build stocks following launches in the UK, US and New Zealand and to help develop two new devices. Eventum Orthopaedics, founded in 2020 by John Naybour and Paul Atherton and based in Ilkley, UK, has developed Quadsense, a device that measures quadriceps forces before and during knee replacement surgery to help surgeons retain muscle balance and restore normal knee function. The company has achieved UK CA approval and the ISO13485 standard for medical devices. Quadsense has been used in 20 operations in New Zealand in conjunction with robotic surgery. Eventum raised £2.5M in a Series A to advance its clinical and commercial progress. The company intends to use the funds to begin production, expand its sales and technical teams, and apply for FDA approval in the US. Eventum Orthopaedics is an Ilkley, Yorkshire, UK–based medtech startup that has developed a device providing real-time measurements during knee replacement operations. The device is intended to enable surgeons to improve decision making in surgery. The company secured funding to finalize development and bring the product to market in 2022. Founders are John Naybour and Paul Atherton; the team has added Mike Cripps as Non-Executive Director and Jon Gonzales as Finance Director. Alan Ashby has been appointed Non-Executive Chair. No operating metrics were disclosed in the article.

Total raised

$10M

Funding rounds

3

Latest round

Equity

Latest activity

Mar 2025